Literature DB >> 25846096

Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin.

Matthew G Oser1, Matthew J Niederst1, Lecia V Sequist1, Jeffrey A Engelman2.   

Abstract

Lung cancer is the most common cause of cancer deaths worldwide. The two broad histological subtypes of lung cancer are small-cell lung cancer (SCLC), which is the cause of 15% of cases, and non-small-cell lung cancer (NSCLC), which accounts for 85% of cases and includes adenocarcinoma, squamous-cell carcinoma, and large-cell carcinoma. Although NSCLC and SCLC are commonly thought to be different diseases owing to their distinct biology and genomic abnormalities, the idea that these malignant disorders might share common cells of origin has been gaining support. This idea has been supported by the unexpected findings that a subset of NSCLCs with mutated EGFR return as SCLC when resistance to EGFR tyrosine kinase inhibitors develops. Additionally, other case reports have described the coexistence of NSCLC and SCLC, further challenging the commonly accepted view of their distinct lineages. Here, we summarise the published clinical observations and biology underlying tumours with combined SCLC and NSCLC histology and cancers that transform from adenocarcinoma to SCLC. We also discuss pre-clinical studies pointing to common potential cells of origin, and speculate how the distinct paths of differentiation are determined by the genomics of each disease.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25846096      PMCID: PMC4470698          DOI: 10.1016/S1470-2045(14)71180-5

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


  64 in total

1.  Effects of an Rb mutation in the mouse.

Authors:  T Jacks; A Fazeli; E M Schmitt; R T Bronson; M A Goodell; R A Weinberg
Journal:  Nature       Date:  1992-09-24       Impact factor: 49.962

2.  Rb family proteins differentially regulate distinct cell lineages during epithelial development.

Authors:  Kathryn A Wikenheiser-Brokamp
Journal:  Development       Date:  2004-08-04       Impact factor: 6.868

3.  Impaired lung branching morphogenesis in the absence of functional EGF receptor.

Authors:  P J Miettinen; D Warburton; D Bu; J S Zhao; J E Berger; P Minoo; T Koivisto; L Allen; L Dobbs; Z Werb; R Derynck
Journal:  Dev Biol       Date:  1997-06-15       Impact factor: 3.582

4.  Small cell carcinoma of the urinary bladder. The Mayo Clinic experience.

Authors:  Nicholas W W Choong; J Fernando Quevedo; Judith S Kaur
Journal:  Cancer       Date:  2005-03-15       Impact factor: 6.860

5.  Combined small-cell and non-small-cell lung cancer.

Authors:  M D Mangum; F A Greco; J D Hainsworth; K R Hande; D H Johnson
Journal:  J Clin Oncol       Date:  1989-05       Impact factor: 44.544

6.  Multiple cells-of-origin of mutant K-Ras-induced mouse lung adenocarcinoma.

Authors:  Kate D Sutherland; Ji-Ying Song; Min Chul Kwon; Natalie Proost; John Zevenhoven; Anton Berns
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-28       Impact factor: 11.205

7.  Epidermal growth factor receptor expression in human lung carcinomas defined by a monoclonal antibody.

Authors:  R E Sobol; R W Astarita; C Hofeditz; H Masui; R Fairshter; I Royston; J Mendelsohn
Journal:  J Natl Cancer Inst       Date:  1987-09       Impact factor: 13.506

8.  Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor.

Authors:  P J Miettinen; J E Berger; J Meneses; Y Phung; R A Pedersen; Z Werb; R Derynck
Journal:  Nature       Date:  1995-07-27       Impact factor: 49.962

9.  Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model.

Authors:  Ralph Meuwissen; Sabine C Linn; R Ilona Linnoila; John Zevenhoven; Wolter J Mooi; Anton Berns
Journal:  Cancer Cell       Date:  2003-09       Impact factor: 31.743

10.  RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer.

Authors:  Matthew J Niederst; Lecia V Sequist; John T Poirier; Craig H Mermel; Elizabeth L Lockerman; Angel R Garcia; Ryohei Katayama; Carlotta Costa; Kenneth N Ross; Teresa Moran; Emily Howe; Linnea E Fulton; Hillary E Mulvey; Lindsay A Bernardo; Farhiya Mohamoud; Norikatsu Miyoshi; Paul A VanderLaan; Daniel B Costa; Pasi A Jänne; Darrell R Borger; Sridhar Ramaswamy; Toshi Shioda; Anthony J Iafrate; Gad Getz; Charles M Rudin; Mari Mino-Kenudson; Jeffrey A Engelman
Journal:  Nat Commun       Date:  2015-03-11       Impact factor: 14.919

View more
  296 in total

1.  Small-cell lung carcinoma transformation of lung adenocarcinoma diagnosed by pericardial effusion: A case report.

Authors:  Ryota Otoshi; Akimasa Sekine; Koji Okudela; Masato Asaoka; Yozo Sato; Satoshi Ikeda; Tomohisa Baba; Shigeru Komatsu; Eri Hagiwara; Takashi Ogura
Journal:  Mol Clin Oncol       Date:  2020-06-03

2.  A combined subtype of small cell lung cancer and adenocarcinoma with epidermal growth factor receptor (EGFR) mutation responds to EGFR tyrosine kinase inhibitors.

Authors:  Yong Zhang; Ling Ye; Huijun Zhang; Xuehua Chen; Haiying Ji; Gang Chen; Lu Zhang; Tengfei Zhang; Meiling Jin
Journal:  J Thorac Dis       Date:  2018-10       Impact factor: 2.895

Review 3.  Drug Resistance to EGFR Inhibitors in Lung Cancer.

Authors:  Osamu Tetsu; Matthew J Hangauer; Janyaporn Phuchareon; David W Eisele; Frank McCormick
Journal:  Chemotherapy       Date:  2016-02-25       Impact factor: 2.544

Review 4.  Tumor-derived exosomes in the regulation of macrophage polarization.

Authors:  Mirza S Baig; Anjali Roy; Sajjan Rajpoot; Dongfang Liu; Rajkumar Savai; Sreeparna Banerjee; Manabu Kawada; Syed M Faisal; Rohit Saluja; Uzma Saqib; Tomokazu Ohishi; Kishore K Wary
Journal:  Inflamm Res       Date:  2020-03-11       Impact factor: 4.575

Review 5.  Biopsy and re-biopsy in lung cancer: the oncologist requests and the role of endobronchial ultrasounds transbronchial needle aspiration.

Authors:  Alessandro Tuzi; Elena Bolzacchini; Matteo B Suter; Alice Giaquinto; Antonio Passaro; Stefania Gobba; Ilaria Vallini; Graziella Pinotti
Journal:  J Thorac Dis       Date:  2017-05       Impact factor: 2.895

Review 6.  Latest development of liquid biopsy.

Authors:  Alvin Ho-Kwan Cheung; Chit Chow; Ka-Fai To
Journal:  J Thorac Dis       Date:  2018-06       Impact factor: 2.895

7.  Lineage Plasticity in Cancer Progression and Treatment.

Authors:  Clémentine Le Magnen; Michael M Shen; Cory Abate-Shen
Journal:  Annu Rev Cancer Biol       Date:  2017-12-01

8.  Transformation to small-cell lung cancer following treatment with icotinib in a patient with lung adenocarcinoma.

Authors:  Hongyang Lu; Bo Chen; Jing Qin; Fajun Xie; Na Han; Zhiyu Huang
Journal:  Oncol Lett       Date:  2018-02-13       Impact factor: 2.967

Review 9.  The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase II (PSMA/GCPII) in cancer and neurological disease.

Authors:  James C Evans; Meenakshi Malhotra; John F Cryan; Caitriona M O'Driscoll
Journal:  Br J Pharmacol       Date:  2016-09-23       Impact factor: 8.739

Review 10.  The pharmacogenomics of drug resistance to protein kinase inhibitors.

Authors:  Nancy K Gillis; Howard L McLeod
Journal:  Drug Resist Updat       Date:  2016-07-05       Impact factor: 18.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.